Literature DB >> 19056836

Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats.

Hongjing Guan1, Peihua Wang, Rutai Hui, Matthew L Edin, Darryl C Zeldin, Dao Wen Wang.   

Abstract

BACKGROUND: Prospective studies have shown that C-reactive protein (CRP) is a predictor of hypertension. Because of confounding variables, a causal linkage between CRP and hypertension has not been clearly shown. We investigated whether high circulating concentrations of human CRP can induce hypertension in rats.
METHODS: We administered a single intravenous injection of adeno-associated virus-green fluorescent protein (AAV-GFP) or AAV-hCRP and measured blood pressure. Using ELISA, we measured serum hCRP, serum endothelin 1 (ET-1), and urine cGMP, and we measured serum nitric oxide (NO) using the Griess method. We recorded heart rate, maximum pressure, arterial elastance, mean aortic pressure, cardiac output, and maximum rate of rise in left ventricular pressure (dP/dt max).
RESULTS: A single injection of AAV-hCRP resulted in efficient and sustained hCRP expression and led to increased blood pressure 2 months after gene transfer that persisted for another 2 months. This effect was associated with decreased NO production, as demonstrated by decreased serum NO concentration and urinary cGMP excretion, and impairment of endothelial-dependent vascular relaxation. CRP transduction also increased expression of angiotensin type 1 receptor, ET-1, and endothelin type A receptor, decreased expression of angiotensin type 2 receptor and endothelial NO synthase in thoracic aortas, and increased arterial stiffness. Ex vivo studies indicated a similar detrimental effect of CRP that was reversed by the NO donor.
CONCLUSION: AAV vector-mediated CRP expression resulted in hypertension mediated through reduced NO production and subsequent alteration in ET-1 and renin-angiotensin system activation. Impaired arterial elasticity may also contribute to CRP-induced hypertension. These results support a causal role for CRP in the pathogenesis of hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19056836      PMCID: PMC2749215          DOI: 10.1373/clinchem.2008.115857

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  28 in total

Review 1.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

2.  Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.

Authors:  R H Böger; S M Bode-Böger; W Thiele; W Junker; K Alexander; J C Frölich
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

3.  Effective arterial elastance as index of arterial vascular load in humans.

Authors:  R P Kelly; C T Ting; T M Yang; C P Liu; W L Maughan; M S Chang; D A Kass
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

4.  Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein.

Authors:  Subodh Verma; Shu-Hong Li; Mitesh V Badiwala; Richard D Weisel; Paul W M Fedak; Ren-Ke Li; Bikramjit Dhillon; Donald A G Mickle
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

5.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase.

Authors:  P L Huang; Z Huang; H Mashimo; K D Bloch; M A Moskowitz; J A Bevan; M C Fishman
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

6.  C-reactive protein and the risk of developing hypertension.

Authors:  Howard D Sesso; Julie E Buring; Nader Rifai; Gavin J Blake; J Michael Gaziano; Paul M Ridker
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

7.  C-reactive protein is associated with arterial stiffness in apparently healthy individuals.

Authors:  Carmel M McEniery; Sharon Wallace; Isla S Mackenzie; John R Cockcroft; Ian B Wilkinson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-03-04       Impact factor: 8.311

8.  Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study.

Authors:  Christina Chrysohoou; Christos Pitsavos; Demosthenes B Panagiotakos; John Skoumas; Christodoulos Stefanadis
Journal:  Am J Hypertens       Date:  2004-07       Impact factor: 2.689

9.  C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Antoni Paul; Kerry W S Ko; Lan Li; Vijay Yechoor; Mark A McCrory; Alexander J Szalai; Lawrence Chan
Journal:  Circulation       Date:  2004-01-26       Impact factor: 29.690

10.  A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis.

Authors:  Subodh Verma; Chao-Hung Wang; Shu-Hong Li; Aaron S Dumont; Paul W M Fedak; Mitesh V Badiwala; Bikramjit Dhillon; Richard D Weisel; Ren-Ke Li; Donald A G Mickle; Duncan J Stewart
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

View more
  22 in total

1.  Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide.

Authors:  Bin Xiao; Xuguang Li; Jiangtao Yan; Xuefeng Yu; Guangtian Yang; Xiao Xiao; James W Voltz; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

2.  Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia.

Authors:  Rui-xue Yang; Shan-ying Huang; Fang-fang Yan; Xiao-ting Lu; Yi-fan Xing; Yan Liu; Yun-fang Liu; Yu-xia Zhao
Journal:  Acta Pharmacol Sin       Date:  2010-09-27       Impact factor: 6.150

3.  Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein.

Authors:  Xuguang Li; Guangtian Yang; Gang Zhao; Bin Wu; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  Hypertens Res       Date:  2011-05-12       Impact factor: 3.872

4.  Transgenic mice expressing an intracellular fluorescent fusion of angiotensin II demonstrate renal thrombotic microangiopathy and elevated blood pressure.

Authors:  K M Redding; B L Chen; A Singh; R N Re; L G Navar; D M Seth; C D Sigmund; W W Tang; J L Cook
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-02       Impact factor: 4.733

5.  C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes.

Authors:  F Liu; H Y Chen; X R Huang; A C K Chung; L Zhou; P Fu; A J Szalai; H Y Lan
Journal:  Diabetologia       Date:  2011-07-09       Impact factor: 10.122

6.  Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome.

Authors:  Michal Pravenec; Takashi Kajiya; Václav Zídek; Vladimír Landa; Petr Mlejnek; Miroslava Simáková; Jan Silhavý; Hana Malínská; Olena Oliyarnyk; Ludmila Kazdová; Jianglin Fan; Jiaming Wang; Theodore W Kurtz
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

7.  C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype.

Authors:  Sridevi Devaraj; Ishwarlal Jialal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-17       Impact factor: 8.311

Review 8.  Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome.

Authors:  Sridevi Devaraj; Simona Valleggi; David Siegel; Ishwarlal Jialal
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

9.  C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction.

Authors:  Sridevi Devaraj; Jung-Mi Yun; Grete Adamson; Jose Galvez; Ishwarlal Jialal
Journal:  Cardiovasc Res       Date:  2009-07-20       Impact factor: 10.787

10.  Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance.

Authors:  Ishwarlal Jialal; Subodh Verma; Sridevi Devaraj
Journal:  Clin Chem       Date:  2008-12-18       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.